Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
This guide clarifies which investors benefit most from target date funds versus index funds, focusing on goals and involvement level.
26,623 articlesLilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
SpaceX is counting down to a defining moment within two weeks. This guide explains what the milestone could mean for ...
EPAM Systems sank this week after reporting earnings that beat the street but offered cautious 2026 guidance. This ar...
GitLab delivered solid revenue growth but offered modest profitability guidance, triggering a sharp stock move. This ...
Intel Arrow Lake Refresh introduces budget-friendly CPUs with stronger cores, bigger caches, and aggressive pricing. ...
Lionsgate faces a pivotal year as it balances streaming momentum with theatrical cycles and debt. This guide breaks d...
Hewlett Packard Enterprise just blew past expectations with stronger revenue and profits, stoking the AI server rally...
A quiet giant in the chip world could deliver a rare investment upside. This guide explains what makes taiwan semicon...
Alphabet raising $84.75 billion marks a bold turn in how tech giants fund AI bets. This article breaks down what it c...
A Tuesday pullback in COP shares left investors weighing oil prices, broker notes, and the long-term outlook for ener...
Fantasy Top captivated Crypto Twitter with a fresh take on fantasy sports powered by blockchain. Now, after two years...
Goldman Sachs updated its governance policy to remove formal DEI criteria from director selection, aligning with peer...